"The combined company will benefit from a formidable research and development pipeline, a significantly broader portfolio of medicines and an expanded presence in key international markets, particularly in high-growth emerging markets. Merck chairman and CEO Richard T. Clark will head the combined company. Merck Chairman, President and Chief Executive Officer Richard T. Clark will lead the combined company. Merck shareholders are expected to own approximately 68 percent of the combined company, and Schering-Plough shareholders are expected to own approximately 32 percent. "We are creating a strong, global healthcare leader built for sustainable growth and success," Clark said in a media statement Monday.